Table 5.
ADMET profiling of best selected peptides.
| SMCG | DECC | TTIT | RTTI | ARNL | TVEV | |
|---|---|---|---|---|---|---|
| Absorption | ||||||
| Blood-brain barrier | BBB+ | BBB+ | BBB+ | BBB+ | BBB+ | BBB+ |
| Human intestinal absorption | HIA- | HIA- | HIA- | HIA- | HIA+ | HIA- |
| Caco-2 permeability | Caco-2- | Caco-2- | Caco-2- | Caco-2- | Caco-2- | Caco-2- |
| P-Glycoprotein substrate | Substrate | Nonsubstrate | Nonsubstrate | Nonsubstrate | Substrate | Nonsubstrate |
| P-Glycoprotein inhibitor | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor |
| Renal organic Cation transporter | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor |
| Metabolism | ||||||
| CYP3A4 substrate | Substrate | Nonsubstrate | Nonsubstrate | Nonsubstrate | Substrate | Nonsubstrate |
| CYP2C9 substrate | Nonsubstrate | Nonsubstrate | Nonsubstrate | Nonsubstrate | Substrate | Nonsubstrate |
| CYP2D6 substrate | Nonsubstrate | Nonsubstrate | Nonsubstrate | Nonsubstrate | Nonsubstrate | Nonsubstrate |
| CYP3A4 inhibition | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor |
| CYP2C9 inhibition | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor |
| CYP2C19 inhibition | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor |
| CYP2D6 inhibition | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor |
| CYP1A2 inhibition | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor | Noninhibitor |
| Toxicity | ||||||
| AMES toxicity | Non-AMES toxic | Non-AMES toxic | Non-AMES toxic | Non-AMES toxic | Non-AMES toxic | Non-AMES toxic |
| Carcinogens | Noncarcinogens | Noncarcinogens | Noncarcinogens | Noncarcinogens | Noncarcinogens | Noncarcinogens |